Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
The article discusses the importance of summarizing content accurately and concisely, focusing on core information while maintaining clarity and avoiding explanatory sentences.
ARCH, biotech's star slugger, snags another $3B for 13th fund
ARCH Venture Partners, known for backing biotech giants like Alnylam and bluebird bio, has raised over $3 billion for its 13th fund, emphasizing investments in AI and precision medicine. Despite some failed ventures, the firm continues to focus on innovative biotechs and preventive healthcare solutions.
Innovation and biotechnology lead Vietnam's healthcare development
Vietnam's healthcare sector aims to align with global R&D trends, emphasizing innovation in mindset, technology, access, and investment. The focus shifts from pharmaceuticals to self-repair mechanisms, leveraging AI and biotechnology. Amendments to the 2016 Law on Pharmacy and $20 billion in economic contribution within 15 years are targeted, with startups playing a crucial role.
Vir Biotechnology stock hits 52-week low at $7.36
Vir Biotechnology's stock hits 52-week low amid market challenges; company appoints new CFO, secures FDA approval, and finalizes licensing deal with Sanofi. Restructuring focuses on viral hepatitis, cutting workforce by 25%. InvestingPro data reveals market cap of $1.01B, negative P/E ratio, and deep negative gross profit margin; analysts advise caution.
Legal reform could woo foreign investment to pharmaceuticals
At VIR's sustainable healthcare conference, experts discussed attracting foreign investment to Vietnam's pharmaceutical sector, emphasizing legal reforms, streamlined regulatory processes, and innovation incentives. Vietnam has attracted $1.8 billion in foreign investment in healthcare, but challenges remain in innovation and regulatory efficiency.
200,000 Shares in Vir Biotechnology, Inc. Bought by Affinity Asset Advisors LLC
Affinity Asset Advisors LLC acquired 200,000 shares of Vir Biotechnology, valued at $1.78M, owning 0.15% as of the latest SEC filing. Other investors also increased their stakes, with 65.32% of the stock owned by hedge funds and institutional investors. Vir Biotechnology's stock opened at $7.54, with a market cap of $1.03B, and reported a quarterly loss of $1.02 per share, missing estimates by $0.13.
Short Cuts
Vir Biotechnology lays off 141 employees, FibroGen cuts 75% of U.S. workforce. A new private school, Hiba Academy, opens in Airbnb’s former SF HQ. Silver Crest Donut Shop, known for its 24/7 service, permanently closes.
Vir Biotechnology Director Janet Napolitano Sells Shares
Janet Napolitano, Vir Biotechnology Director, sold 12,190 shares for $95,032 on Sept 9, 2024, avg. price $7.7959/share. Now owns 11,616 shares. Sale under Rule 10b5-1 plan adopted June 10, 2024.
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With ...
Vir Biotechnology closed a strategic agreement with Sanofi, gaining exclusive worldwide licenses to three clinical-stage masked T-cell engagers (TCEs) for cancer treatments and the PRO-XTEN masking platform for oncology and infectious disease. The TCEs include SAR446309 (HER2-targeted), SAR446329 (PSMA-targeted), and SAR446368 (EGFR-targeted), with clinical studies underway or planned. Key Sanofi employees with expertise in TCEs and the PRO-XTEN platform will join Vir.
Vir Biotechnology Appoints Jason O'Byrne As CFO
Vir Biotechnology Inc. appoints Jason O'Byrne as Chief Financial Officer, effective October 2, following his role as CFO at Caribou Biosciences, Inc.
© Copyright 2024. All Rights Reserved by MedPath